论文部分内容阅读
目的 :研究前列腺素E1脂微球载体制剂 (LipoPGE1,凯时 )治疗糖尿病周围神经病变的临床疗效及观察其不良反应。方法 :对确诊为糖尿病合并周围神经病变的 18例患者 ,给予LipoPGE110 μg/d ,共 2周。对照组 2 2例给予维生素B110mg、维生素B12 0 .5mg/d。 结果 :治疗组应用LipoPGE1治疗 2周后 ,患者主观症状和体征有较明显改善 ,总有效率达 88.9% ,而对照组有效率仅达 40 .9% ,两者比较统计学上有显著性差异 (P <0 .0 5 )。正中神经和腓总神经MCV ,正中神经和腓浅神经SCV 4项神经传导速度 ,治疗组治疗前后比较有显著差异 (P <0 .0 5 ) ,对照治疗前后比较无明显变化 (P >0 .0 5 )。药物治疗过程中未见明显不良反应。结论 :LipoPGE1是治疗糖尿病周围神经病变有效且安全的药物
OBJECTIVE: To study the clinical efficacy of LipoPGE1 (LipoPGE1) in the treatment of diabetic peripheral neuropathy and its adverse reactions. Methods: 18 patients diagnosed with diabetic peripheral neuropathy were given LipoPGE 110 μg / d for 2 weeks. Control group 2 2 cases given vitamin B110mg, vitamin B12 0 .5mg / d. Results: The treatment group treated with LipoPGE1 for 2 weeks, the subjective symptoms and signs of patients improved significantly, the total effective rate was 88.9%, while the control group was only 40.9% effective rate, the two statistically significant difference (P <0. 05). The median nerve and peroneal nerve MCV, median nerve and superficial SCV 4 nerve conduction velocity, the treatment group before and after treatment were significantly different (P <0. 05), before and after the control treatment showed no significant change (P> 0. 0 5). No obvious adverse reactions during the drug treatment. Conclusion: LipoPGE1 is effective and safe for the treatment of diabetic peripheral neuropathy